Eli Lilly is considering all these risks and planning accordingly, and doing so years in advance. That's also why the ...

Since early August, the world’s most valuable pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), has put on a stellar ...

But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study.

Eli Lilly (LLY) has shown considerable rally potential, with several occurrences of its stock climbing over 30% in less than ...

As the oral GLP-1 race intensifies, Eli Lilly has slimmed back the number of phase 2 trials it is conducting for one of its contenders. The Big Pharma had been running three midstage studies of the ...

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection ...

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

Abivax (ABVX) stock surged on Obefazimod trial success and takeover rumors. Learn if valuation risks now outweigh reward.

INDIANAPOLIS, May 8, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced executive leadership transitions that will further enhance the company's ability to drive sustained, ...

Eli Lilly's oral pill helped maintain weight loss in patients switching from its GLP-1 injection, Zepbound, and rival Novo ...